David J. Sas

2.2k total citations · 1 hit paper
39 papers, 974 citations indexed

About

David J. Sas is a scholar working on Pulmonary and Respiratory Medicine, Pediatrics, Perinatology and Child Health and Nephrology. According to data from OpenAlex, David J. Sas has authored 39 papers receiving a total of 974 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 18 papers in Pediatrics, Perinatology and Child Health and 13 papers in Nephrology. Recurrent topics in David J. Sas's work include Kidney Stones and Urolithiasis Treatments (23 papers), Pediatric Urology and Nephrology Studies (14 papers) and Biomedical Research and Pathophysiology (9 papers). David J. Sas is often cited by papers focused on Kidney Stones and Urolithiasis Treatments (23 papers), Pediatric Urology and Nephrology Studies (14 papers) and Biomedical Research and Pathophysiology (9 papers). David J. Sas collaborates with scholars based in United States, United Kingdom and Israel. David J. Sas's co-authors include Ibrahim F. Shatat, Peter C. Harris, John K. Orak, Thomas C. Hulsey, John C. Lieske, Prince Singh, Dawn S. Milliner, Lawrence Copelovitch, Ron Keren and Gregory E. Tasian and has published in prestigious journals such as SHILAP Revista de lepidopterología, Kidney International and Journal of the American Society of Nephrology.

In The Last Decade

David J. Sas

37 papers receiving 951 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The genetics of kidney stone disease and nephrocalcinosis

2021 136 citations Prince Singh, Peter C. Harris et al. profile →

Peers

Countries citing papers authored by David J. Sas

Since Specialization

Citations

This map shows the geographic impact of David J. Sas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Sas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Sas more than expected).

Fields of papers citing papers by David J. Sas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Sas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Sas. The network helps show where David J. Sas may publish in the future.

Co-authorship network of co-authors of David J. Sas

This figure shows the co-authorship network connecting the top 25 collaborators of David J. Sas. A scholar is included among the top collaborators of David J. Sas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Sas. David J. Sas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8) 2025 ·Pediatric Nephrology ·David J. Sas, Sevcan A. Bakkaloğlu, Vladimir Belostotsky, Wesley Hayes, Gema Ariceta, Jing Zhou, (unknown)	2
2	Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory 2024 ·Kidney International Reports ·Barbara Cellini, Michelle A. Baum, Yaacov Frishberg, Jaap W. Groothoff, Peter C. Harris, Sally A. Hulton, Felix Knauf, John Knight, John C. Lieske, W. Todd Lowther, Shabbir H. Moochhala, Lama Nazzal, Gregory E. Tasian, Jonathan M. Whittamore, David J. Sas	2
3	Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial 2024 ·Frontiers in Pediatrics ·Yaacov Frishberg, Wesley Hayes, Hadas Shasha‐Lavsky, David J. Sas, Mini Michael, Anne‐Laure Sellier‐Leclerc, Julien Hogan, (unknown), John M. Gansner, Daniella Magen	1
4	The Site and Type of CLCN5 Genetic Variation Impact the Resulting Dent Disease-1 Phenotype 2023 ·Kidney International Reports ·(unknown), Jennifer Arroyo, Andrea G. Cogal, Franca Anglani, Hee Gyung Kang, David J. Sas, Peter C. Harris, John C. Lieske	9
5	Examination of nutritional factors associated with urolithiasis risk in plant based meat alternatives marketed to children and infants 2023 ·Journal of Pediatric Urology ·(unknown), (unknown), Aaron M. Potretzke, David J. Sas, Patricio C. Gargollo, Candace F. Granberg, Kevin Koo	3
6	Successful Treatment of Primary Hyperoxaluria Type 2 with a Combined Liver and Kidney Transplant 2023 ·Kidney International Reports ·(unknown), David J. Sas, Dawn S. Milliner, John C. Lieske	7
7	Patient Satisfaction Scores Impact Pediatrician Practice Patterns, Job Satisfaction, and Burnout 2022 ·Clinical Pediatrics ·David J. Sas, Imad Absah, Sean M. Phelan, Avni Y. Joshi, Ana L. Creo, Supriya Behl, Kristine T. Hanson, (unknown)	3
8	Kidney Cysts in Hypophosphatemic Rickets With Hypercalciuria: A Case Series 2022 ·Kidney Medicine ·Christian Hanna, Theodora A. Potretzke, (unknown), Laureano J. Rangel, Jennifer Arroyo, (unknown), Peter J. Tebben, Andrea G. Cogal, Vicente E. Torres, Peter C. Harris, David J. Sas, John C. Lieske, Dawn S. Milliner, Fouad T. Chebib	6
9	Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1 2022 ·American Journal of Kidney Diseases ·Prince Singh, Lisa E. Vaughan, Phillip J. Schulte, David J. Sas, Dawn S. Milliner, John C. Lieske	4
10	Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial 2022 ·Pediatric Nephrology ·Wesley Hayes, David J. Sas, Daniella Magen, Hadas Shasha‐Lavsky, Mini Michael, Anne‐Laure Sellier‐Leclerc, Julien Hogan, (unknown), Marianne T. Sweetser, John M. Gansner, Tracy L. McGregor, Yaacov Frishberg	30
11	Acute Kidney Injury and Renal Replacement Therapy After Fontan Operation 2021 ·The American Journal of Cardiology ·Talha Niaz, Elizabeth H. Stephens, Stephen J. Gleich, Joseph A. Dearani, Jonathan N. Johnson, David J. Sas, Stephen Bly, David J. Driscoll, Frank Cetta	6
12	24-Hydroxylase Deficiency Due toCYP24A1Sequence Variants: Comparison With Other Vitamin D−mediated Hypercalcemia Disorders 2021 ·Journal of the Endocrine Society ·(unknown), Lisa E. Vaughan, Peter J. Tebben, David J. Sas	10
13	High Prevalence of Kidney Cysts in Patients With CYP24A1 Deficiency 2021 ·Kidney International Reports ·Christian Hanna, Theodora A. Potretzke, Andrea G. Cogal, (unknown), Peter J. Tebben, Vicente E. Torres, John C. Lieske, Peter C. Harris, David J. Sas, Dawn S. Milliner, Fouad T. Chebib	10
14	A toddler with severe hypercalcemia and pyelonephritis: Answers 2020 ·Pediatric Nephrology ·(unknown), (unknown), Faris Hashim, David J. Sas, Christian Hanna	1
15	Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease 2016 ·Pediatric Nephrology ·Cheryl L. Tran, Sanjeev Sethi, David Murray, Carl H. Cramer, David J. Sas, Maria Alice V. Willrich, Richard J. Smith, Fernando C. Fervenza	10
16	Clinical, demographic, and laboratory characteristics of children with nephrolithiasis 2015 ·Urolithiasis ·David J. Sas, (unknown), (unknown), Laura A. Lindsay, Amy H. Wahlquist	36
17	An Update on the Changing Epidemiology and Metabolic Risk Factors in Pediatric Kidney Stone Disease 2011 ·Clinical Journal of the American Society of Nephrology ·David J. Sas	101
18	Increasing Incidence of Kidney Stones in Children Evaluated in the Emergency Department 2010 ·The Journal of Pediatrics ·David J. Sas, Thomas C. Hulsey, Ibrahim F. Shatat, John K. Orak	184
19	Effect of claudins 6 and 9 on paracellular permeability in MDCK II cells 2008 ·American Journal of Physiology-Regulatory, Integrative and Comparative Physiology ·David J. Sas, (unknown), Orson W. Moe, Michel Baum	37
20	Pseudomonas aeruginosa septic shock secondary to “Gripe Water” ingestion 2004 ·The Pediatric Infectious Disease Journal ·David J. Sas, (unknown), Richard H. Schwartz	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact